Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dan who wrote (95)	3/11/1998 6:43:00 PM
From: Dan	Read Replies (1) \| Respond to of 279

Today's press release: IMUTEC PHARMA ANNOUNCES COMPLETION OF CLINICAL TRIAL ENROLLMENT TSE / ME: IMT NASDAQ: IMUTF TORONTO, ONTARIO March 11, 1998 - Imutec Pharma Inc. today announced that it has completed patient enrollment for its Phase I/II pancreatic cancer trial at the Rush Presbyterian St. Luke's Medical Center in Chicago. The completion of this Phase I/II trial marks the achievement of an other significant milestone by Imutec Pharma. The results of this trial will aid in discussions with potential partners regarding the licensing of marketing and distribution rights for Virulizinr, which is in line with the Company's business strategy of out-licensing products prior to Phase III clinical trials. "I am pleased to report that enrollment of our current trial is now complete," said Philippe Lacaille, President & CEO at Imutec Pharma. "The required number of evaluable patients have completed the treatment period, according to the design of the study. We will now be able to complete the data analysis in order to determine the safety and efficacy of Virulizinr. We anticipate being able to communicate these results shortly." In July 1996, Imutec Pharma initiated a Phase I/II clinical trial to evaluate the biological activity of Virulizinr in patients with pancreatic cancer, and to monitor the safety and efficacy of the treatment. The trial was designed as a non-comparative, escalating dose study involving advanced stage patients who had failed standard or investigational treatments. In November, 1997, Imutec Pharma reported an interim efficacy analysis of its current Phase I/II trial. The data obtained at that time indicated the same trend in safety and efficacy as seen in Imutec's previous pancreatic cancer study. Imutec Pharma Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for the treatment of cancer and certain viral diseases. Through an active acquisition and in-licensing program, Imutec Pharma's goal is to build and clinically develop a portfolio of innovative drugs targeted at life-threatening diseases. Thereafter, Imutec Pharma intends to undertake late stage clinical development and marketing in cooperation with strategic pharmaceutical partners. Founded in 1986, Imutec Pharma Inc. is a public company listed on the Toronto Stock Exchange and the Montreal Stock Exchange under the symbol IMT and on the NASDAQ exchange under the symbol IMUTF. Except for historical information, this press release contains forward-looking statements which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Imutec Pharma's press releases are available through the Company's Internet site: imutec.com For further information, please contact: Paul W. Truscott, Jr. Associate, Corporate Communications Imutec Pharma, Inc. 1285 Morningside Avenue Scarborough, ON M1B 3W2 Tel 416-724-1100 x251 Fax 416-724-1167